Methocinnamox is a Potent and Long-Acting Antagonist that can Prevent and Reverse Opioid-Induced Respiratory Depression.
作者信息
Carr James A, Morgan Daniel J
机构信息
Department of Biology, Texas Tech University, Lubbock, Texas (J.A.C.) and Department of Biomedical Sciences, Marshall University, Huntington, West Virginia (D.J.M.).
Department of Biology, Texas Tech University, Lubbock, Texas (J.A.C.) and Department of Biomedical Sciences, Marshall University, Huntington, West Virginia (D.J.M.)
出版信息
J Pharmacol Exp Ther. 2024 Sep 18;391(1):1-3. doi: 10.1124/jpet.124.002205.
Abstract
摘要
相似文献
1
Methocinnamox is a Potent and Long-Acting Antagonist that can Prevent and Reverse Opioid-Induced Respiratory Depression.甲氧辛胺是一种强效长效拮抗剂，可预防和逆转阿片类药物引起的呼吸抑制。
J Pharmacol Exp Ther. 2024 Sep 18;391(1):1-3. doi: 10.1124/jpet.124.002205.
2
Comparison of the -Opioid Receptor Antagonists Methocinnamox and Naloxone to Reverse and Prevent the Ventilatory Depressant Effects of Fentanyl, Carfentanil, 3-Methylfentanyl, and Heroin in Male Rats.比较阿片受体拮抗剂甲氧辛胺和纳洛酮对雄性大鼠芬太尼、卡芬太尼、3-甲基芬太尼和海洛因呼吸抑制作用的逆转和预防效果。
J Pharmacol Exp Ther. 2024 Sep 18;391(1):4-17. doi: 10.1124/jpet.123.002032.
3
Reversal of morphine-induced respiratory depression with the µ-opioid receptor antagonist naloxonazine engenders excitation and instability of breathing.用μ阿片受体拮抗剂纳洛嗪逆转吗啡引起的呼吸抑制会导致呼吸兴奋和不稳定。
Am J Physiol Lung Cell Mol Physiol. 2025 Jul 1;329(1):L97-L111. doi: 10.1152/ajplung.00045.2025. Epub 2025 May 14.
4
Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel -Opioid Receptor Antagonist Methocinnamox in Rhesus Monkeys.新型阿片受体拮抗剂甲硫环嗪逆转和预防海洛因在恒河猴中的呼吸抑制作用。
J Pharmacol Exp Ther. 2019 Feb;368(2):229-236. doi: 10.1124/jpet.118.253286. Epub 2018 Nov 21.
5
Methocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats.甲氧辛胺逆转并预防大鼠芬太尼诱导的呼吸抑制。
J Pharmacol Exp Ther. 2021 Apr;377(1):29-38. doi: 10.1124/jpet.120.000387. Epub 2021 Jan 11.
6
Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest.阿片类药物过量：纳洛酮逆转呼吸抑制和预防心脏骤停的局限性。
Anesthesiology. 2023 Sep 1;139(3):342-353. doi: 10.1097/ALN.0000000000004622.
7
Buprenorphine Pharmacodynamics: A Bridge to Understanding Buprenorphine Clinical Benefits.丁丙诺啡的药效学：理解丁丙诺啡临床益处的桥梁。
Drugs. 2025 Feb;85(2):215-230. doi: 10.1007/s40265-024-02128-y. Epub 2025 Jan 28.
8
Searching for Synthetic Opioid Rescue Agents. 2: Identification of an Ultra-Potent Synthetic Opioid Rescue Agent.寻找合成阿片类救援药物。2：一种超高效合成阿片类救援药物的鉴定。
J Med Chem. 2025 Jun 26;68(12):13057-13074. doi: 10.1021/acs.jmedchem.5c01108. Epub 2025 Jun 11.
9
Antinociceptive effects of fentanyl and nonopioid drugs in methocinnamox-treated rats.芬太尼和非阿片类药物在甲氧基肉桂酰胺处理的大鼠中的镇痛作用。
Drug Alcohol Depend. 2024 Jul 1;260:111320. doi: 10.1016/j.drugalcdep.2024.111320. Epub 2024 Apr 29.
10
Time Course of Reversal of Fentanyl-Induced Respiratory Depression in Healthy Subjects by Intramuscular Nalmefene and Intramuscular and Intranasal Naloxone.健康受试者中，肌肉注射纳美芬以及肌肉注射和鼻内注射纳洛酮对芬太尼所致呼吸抑制的逆转时间进程。
J Clin Pharmacol. 2025 Feb;65(2):206-216. doi: 10.1002/jcph.6132. Epub 2024 Sep 30.
本文引用的文献
1
Reversal of Opioid-Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal Naloxone.健康志愿者中阿片类药物引起的呼吸抑制的逆转：鼻内纳美芬与鼻内纳洛酮的比较。
J Clin Pharmacol. 2024 Jul;64(7):828-839. doi: 10.1002/jcph.2421. Epub 2024 Mar 4.
2
Comparison of the -Opioid Receptor Antagonists Methocinnamox and Naloxone to Reverse and Prevent the Ventilatory Depressant Effects of Fentanyl, Carfentanil, 3-Methylfentanyl, and Heroin in Male Rats.比较阿片受体拮抗剂甲氧辛胺和纳洛酮对雄性大鼠芬太尼、卡芬太尼、3-甲基芬太尼和海洛因呼吸抑制作用的逆转和预防效果。
J Pharmacol Exp Ther. 2024 Sep 18;391(1):4-17. doi: 10.1124/jpet.123.002032.
3
Daily methocinnamox treatment dose-dependently attenuates fentanyl self-administration in rhesus monkeys.每日美沙酮处理剂量依赖性地减弱恒河猴的芬太尼自我给药。
Neuropharmacology. 2024 Feb 1;243:109777. doi: 10.1016/j.neuropharm.2023.109777. Epub 2023 Nov 8.
4
Pharmacokinetic Properties of an FDA-approved Intranasal Nalmefene Formulation for the Treatment of Opioid Overdose.一种经美国食品药品监督管理局批准的用于治疗阿片类药物过量的鼻腔内纳美芬制剂的药代动力学特性。
Clin Pharmacol Drug Dev. 2024 Jan;13(1):58-69. doi: 10.1002/cpdd.1312. Epub 2023 Jul 27.
5
Attenuation of the Positive-Reinforcing Effects of Ultra-Potent Fentanyl Analogs, Along with Those of Fentanyl and Heroin, During Daily Treatment with Methocinnamox in Rhesus Monkeys.美沙酮每日治疗削弱了超强效芬太尼类似物、芬太尼和海洛因的正强化效应。
J Pharmacol Exp Ther. 2023 Mar;384(3):363-371. doi: 10.1124/jpet.122.001267. Epub 2022 Dec 27.
6
The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review.甲氧辛胺作为阿片类物质使用障碍未来治疗方法的潜力：一项叙述性综述
Pharmacy (Basel). 2022 Apr 19;10(3):48. doi: 10.3390/pharmacy10030048.
7
Effects of Daily Methocinnamox Treatment on Fentanyl Self-Administration in Rhesus Monkeys.每日美沙酮治疗对恒河猴芬太尼自我给药的影响。
J Pharmacol Exp Ther. 2022 Aug;382(2):181-187. doi: 10.1124/jpet.122.001233. Epub 2022 May 28.
8
Treatment of opioid overdose: current approaches and recent advances.阿片类药物过量治疗：当前方法和最新进展。
Psychopharmacology (Berl). 2022 Jul;239(7):2063-2081. doi: 10.1007/s00213-022-06125-5. Epub 2022 Apr 7.
9
Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox.新型配体甲氧基肉桂诺对 μ 阿片受体的长期拮抗和变构调节。
Pharmacol Res Perspect. 2021 Dec;9(6):e00887. doi: 10.1002/prp2.887.
10
The Birth of Naloxone: An Intellectual History of an Ambivalent Opioid.纳洛酮的诞生：一种矛盾阿片类药物的知识史。
Camb Q Healthc Ethics. 2021 Oct;30(4):637-650. doi: 10.1017/S0963180121000116.
Zotero 插件